Merck & Co Inc. (MRK) and Daiichi Sankyo on Thursday said that the companies have withdrawn their application to the U.S. Food and Drug Administration (FDA) seeking permission to commercialize ...

Within a few years, these last spent fuel rods can then be safely transported off-site for storage, reprocessing and the manufacturing of fresh reactor fuel. That’s projected to be 2026 for Unit ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

Although with e.g. Fukushima Daiichi’s triple meltdown the zircalloy fuel rods were partially destroyed, it was the formation of hydrogen gas inside the reactor vessels and the hydrogen ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.

The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.

Daiichi and AZ’s aim of improving the broader public’s understanding of life with breast cancer was also the impetus for the choice to debut the ad during Thursday Night Football, which last ...

In 2020, Daiichi Sankyo and AZ agreed to carry out a clinical trial exploring the combination of Tagrisso with patritumab deruxtecan in patients with this form of cancer who have specific EGFR ...

The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are important because many patients do not live long enough to receive a second-line cancer therapy. By Frank ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effe ...

Daiichi Sankyo's Board of Directors appointed Okuzawa as the new CEO at the board meeting on January 31, in order to ensure the solid achievement of FY2025 goals and to strengthen its management ...